某院恶性实体肿瘤高致吐风险方案化疗恶心呕吐预处理合理性分析  

The rationality on the prevention of nausea and vomiting induced by high emetic risk chemotherapy in our hospital

作　　者：李军云 段韶军 赵牛河 LI Junyun;DUAN Shaojun;ZHAO Niuhe(Jincheng People's Hospital,Jincheng 048026,China;Jincheng Emergency Medical Rescue Center,Jincheng 048026,China)

机构地区：[1]晋城市人民医院,山西晋城048026 [2]晋城市紧急医疗救援中心,山西晋城048026

出　　处：《临床医药实践》2021年第6期434-438,共5页Proceeding of Clinical Medicine

摘　　要：目的:探讨恶性实体肿瘤行高致吐风险方案化疗病历恶心、呕吐预处理用药的合理性。方法:选取2019年1月—2019年12月确诊为恶性实体肿瘤并行高致吐风险方案化疗的患者,将其恶心、呕吐预处理用药情况与指南推荐方案、说明书用法用量等进行比较,分析其合理性。结果:恶性实体肿瘤高致吐风险方案化疗急性、延迟性、多日连续化疗恶心和呕吐预处理方案合理率均不足25%,与指南推荐方案尚有较大差距。药物选择、给药剂量、给药频次、疗程等方面亦存在不规范因素。结论:恶性实体肿瘤高致吐风险方案化疗恶心、呕吐预处理遵指南用药率较低,目前仍处于以甲氧氯普胺联合5-羟色胺(5-HT_(3))受体拮抗剂及地塞米松为主的阶段,指南推荐的新型止吐药神经激肽-1(NK-1)受体拮抗剂、奥氮平、沙利度胺等鲜少使用,说明基层医院高致吐风险方案化疗恶心、呕吐遵指南规范化预处理亟待提高。Objective:To explore and analyze the rationality on the prevention of nausea and vomiting for patients receiving high emetic risk chemotherapy in jincheng people's hospital from 20191st January to 31st December.Methods:The cases diagnosed for malignant solid tumor and treated with high emetic risk chemotherapy during January 2019 to December 2019 were selected,and then the rationality were analyzed by comparing the prevention of nausea/vomiting in our cases with the recommended schemes in the guidelines and the usages of drug instructions.Results:The rationality on the prevention of acute、delayed and multiday continuous nausea and vomiting induced by high emetic risk chemotherapy in our hospital were less than 25%,which was still far from the recommended schemes.There were also man y unreasonable factors in drug selections,dosages,the frequency and courses of treatment.Conclusion:The rationality on the prevention of nausea and vomiting induced by high emetic risk chemotherapy for malignant solid tumor in our hospital was very low.Currently,it was still remained in the combination metoclopramide with 5-hydroxytryptamine(5-HT_(3))antagonist and dexamethasone.These drugs such as neurokinin receptor(NK-1)receptor antagonist,olanzapine and thalidomide recommended by the guidelines were rarely used.So the standardized prevention of nausea and vomiting induced by high emetic risk chemotherapy in primary hospitals still needs to be improved.

关 键 词：恶性实体肿瘤 静脉化疗 高致吐风险方案化疗 化疗相关性恶心呕吐 用药合理性 

分 类 号：R73[医药卫生—肿瘤]